Consistent with these observations, supplementing C4-treated cells with exogenous ATP partially rescued cancer cell viability while equivalent concentrations of a non-hydrolyzable ATP analog did not (Figure S9B), providing further experimental evidence in support of a direct role for metabolic disruption in the SDL action of IGF2BP2. The gene discussed is IGF2BP2; the disease is cancer.